Venus Medtech (Hangzhou), Inc. Class H
HHKEX:25001.03
HKD
+0.02
(+1.98%)
Venus Medtech (Hangzhou), Inc. Class H
HKEX:2500
(Hong Kong Exchange)
Recent
price
1.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Venus Medtech (Hangzhou) Inc. is a prominent entity in the development and global commercialization of transcatheter medical devices for structural heart conditions. The company's innovative portfolio includes several commercially available solutions, such as the VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe systems designed for transcatheter aortic valve replacement (TAVR) to address severe aortic stenosis. Furthermore, its VenusP-Valve, a unique self-expanding transcatheter pulmonary valve replacement (TPVR) system, is utilized for managing pulmonary regurgitation, having achieved significant international market penetration across Europe and other regions. The company also offers essential procedural accessories like expandable catheter sheaths and balloon catheters. Beyond its marketed offerings, Venus Medtech maintains a robust pipeline of next-generation therapies. This includes advanced TAVR product candidates such as Venus-Vitae and Venus-PowerX, both dry-valve systems currently advancing through pivotal clinical trials. The innovative Cardiovalve platform is under clinical investigation for transcatheter mitral and tricuspid valve replacement (TMVR and TTVR), with studies progressing across multiple international centers. Additionally, the company is at the forefront of developing the Liwen RF ablation system for treating hypertrophic cardiomyopathy and renal denervation solutions for hypertension management. Established in 2009 and based in Hangzhou, People's Republic of China, Venus Medtech continues to expand its global footprint, with international sales contributing a growing portion of its revenue and its products available in numerous markets worldwide. The firm's commitment to innovation is underlined by its extensive intellectual property portfolio and recent recognition for high-value patent cultivation. A strategic decision in November 2025 to sell an industrial park property aims to enhance financial flexibility and sharpen focus on core heart valve technologies.